July 16, 2024
4 min watch
We had been unable to course of your request. Please strive once more later. Should you proceed to have this problem please contact customerservice@slackinc.com.
On this video, Eric Winer, MD, discusses the outcomes of the TakeAim examine into acute myeloid leukemia, which he helped current at ASCO Annual Assembly.
Winer, a medical oncologist at Dana-Farber Most cancers Institute, highlighted the examine, which examined using emavusertib (Curis) in sufferers with acute myeloid leukemia who’ve skilled two various kinds of mutations.
“I feel this can be a very thrilling molecule, and I feel that after we mix emavusertib with different brokers, we will see some very nice outcomes and powerful efficacy, and that is what is going on to be shifting ahead in bigger section two trials proper now,” Winer stated.
Revealed by:
We had been unable to course of your request. Please strive once more later. Should you proceed to have this problem please contact customerservice@slackinc.com.
